Literature DB >> 35902637

PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine.

Ramin Sedaghat Herati1, David A Knorr2,3, Laura A Vella4,5, Luisa Victoria Silva5, Lakshmi Chilukuri3, Sokratis A Apostolidis5,6, Alexander C Huang5,6,7, Alexander Muselman6,8, Sasikanth Manne5,9, Oliva Kuthuru5,9, Ryan P Staupe5, Sharon A Adamski5,9, Senthil Kannan10, Raj K Kurupati10, Hildegund C J Ertl10, Jeffrey L Wong2,3, Stylianos Bournazos2, Suzanne McGettigan6,7, Lynn M Schuchter6,7, Ritesh R Kotecha3, Samuel A Funt3, Martin H Voss3, Robert J Motzer3, Chung-Han Lee3, Dean F Bajorin3, Tara C Mitchell6,7, Jeffrey V Ravetch11, E John Wherry12,13.   

Abstract

Anti-programmed death-1 (anti-PD-1) immunotherapy reinvigorates CD8 T cell responses in patients with cancer but PD-1 is also expressed by other immune cells, including follicular helper CD4 T cells (Tfh) which are involved in germinal centre responses. Little is known, however, about the effects of anti-PD-1 immunotherapy on noncancer immune responses in humans. To investigate this question, we examined the impact of anti-PD-1 immunotherapy on the Tfh-B cell axis responding to unrelated viral antigens. Following influenza vaccination, a subset of adults receiving anti-PD-1 had more robust circulating Tfh responses than adults not receiving immunotherapy. PD-1 pathway blockade resulted in transcriptional signatures of increased cellular proliferation in circulating Tfh and responding B cells compared with controls. These latter observations suggest an underlying change in the Tfh-B cell and germinal centre axis in a subset of immunotherapy patients. Together, these results demonstrate dynamic effects of anti-PD-1 therapy on influenza vaccine responses and highlight analytical vaccination as an approach that may reveal underlying immune predisposition to adverse events.
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35902637     DOI: 10.1038/s41590-022-01274-3

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   31.250


  61 in total

Review 1.  T follicular helper cell differentiation, function, and roles in disease.

Authors:  Shane Crotty
Journal:  Immunity       Date:  2014-10-16       Impact factor: 31.745

2.  Follicular B helper T cell activity is confined to CXCR5(hi)ICOS(hi) CD4 T cells and is independent of CD57 expression.

Authors:  Ata-Ur Rasheed; Hans-Peter Rahn; Federica Sallusto; Martin Lipp; Gerd Müller
Journal:  Eur J Immunol       Date:  2006-07       Impact factor: 5.532

Review 3.  T Follicular Helper Cell Biology: A Decade of Discovery and Diseases.

Authors:  Shane Crotty
Journal:  Immunity       Date:  2019-05-21       Impact factor: 31.745

Review 4.  Follicular helper CD4 T cells (TFH).

Authors:  Shane Crotty
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

5.  T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.

Authors:  Alexander C Huang; Michael A Postow; Robert J Orlowski; Rosemarie Mick; Bertram Bengsch; Sasikanth Manne; Wei Xu; Shannon Harmon; Josephine R Giles; Brandon Wenz; Matthew Adamow; Deborah Kuk; Katherine S Panageas; Cristina Carrera; Phillip Wong; Felix Quagliarello; Bradley Wubbenhorst; Kurt D'Andrea; Kristen E Pauken; Ramin S Herati; Ryan P Staupe; Jason M Schenkel; Suzanne McGettigan; Shawn Kothari; Sangeeth M George; Robert H Vonderheide; Ravi K Amaravadi; Giorgos C Karakousis; Lynn M Schuchter; Xiaowei Xu; Katherine L Nathanson; Jedd D Wolchok; Tara C Gangadhar; E John Wherry
Journal:  Nature       Date:  2017-04-10       Impact factor: 49.962

6.  Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.

Authors:  Morganna Freeman-Keller; Youngchul Kim; Heather Cronin; Allison Richards; Geoffrey Gibney; Jeffrey S Weber
Journal:  Clin Cancer Res       Date:  2015-10-07       Impact factor: 12.531

7.  Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.

Authors:  Elena Verzoni; Giacomo Cartenì; Enrico Cortesi; Diana Giannarelli; Andrea De Giglio; Roberto Sabbatini; Sebastiano Buti; Sabrina Rossetti; Francesco Cognetti; Francesca Rastelli; Alberto Sobrero; Daniele Turci; Cora N Sternberg; Camillo Porta; Federico Cappuzzo; Giampaolo Tortora; Davide Tassinari; Stefano Panni; Antonio Pazzola; Gianmarco Surico; Alessandra Raimondi; Ugo De Giorgi; Giuseppe Procopio
Journal:  J Immunother Cancer       Date:  2019-04-03       Impact factor: 13.751

Review 8.  A guide to cancer immunotherapy: from T cell basic science to clinical practice.

Authors:  Alex D Waldman; Jill M Fritz; Michael J Lenardo
Journal:  Nat Rev Immunol       Date:  2020-05-20       Impact factor: 53.106

9.  Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.

Authors:  Koji Haratani; Hidetoshi Hayashi; Yasutaka Chiba; Keita Kudo; Kimio Yonesaka; Ryoji Kato; Hiroyasu Kaneda; Yoshikazu Hasegawa; Kaoru Tanaka; Masayuki Takeda; Kazuhiko Nakagawa
Journal:  JAMA Oncol       Date:  2018-03-01       Impact factor: 31.777

View more
  1 in total

1.  A path forward to improving the specificity of immunotherapies.

Authors:  Brittany Barber; Florian Mair; Martin Prlic
Journal:  Clin Transl Med       Date:  2022-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.